Structure Therapeutics
GPCR
26.68
-0.79
-2.88%
Structure Therapeutics
US · GPCR
#2815 by market cap
Listed 2023
26.68
-0.79
-2.88%
Live - 5344 symbols - heartbeat 442s ago
· 2026-10-08 07:34
Pre-market
26.34
-1.26%
After-hours
27.00
+1.20%
Overnight
26.78
+0.37%
- Market cap
- 1.90B
- P/E (TTM)i
- -8.81
- P/Bi
- 1.40
- EPSi
- -2.40
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on GPCR?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 6 years
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.54M | 8.59M | 16.37M | 32.67M | 49.41M | 61.55M |
| Research & development | 12.36M | 29.11M | 36.19M | 70.10M | 108.81M | 225.26M |
| Operating profit | -15.91M | -37.70M | -52.56M | -102.78M | -158.23M | -186.81M |
| Pretax profit | -15.74M | -37.82M | -51.30M | -89.38M | -122.22M | -140.69M |
| Tax | 138.00K | 231.00K | 17.00K | 236.00K | 310.00K | 515.00K |
| Net profit | -16.04M | -38.05M | -51.32M | -89.62M | -122.53M | -141.20M |
| Basic EPS | -1 | -2 | -1 | -2 | -2 | -2 |
| Diluted EPS | -0.64 | -1.72 | -1.38 | -2.43 | -2.34 | -2.40 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 13.44M | 15.74M | 14.80M | 17.57M | 22.87M | 18.57M |
| Research & development | 42.87M | 54.71M | 58.99M | 68.69M | 66.51M | 100.06M |
| Operating profit | -56.31M | -70.45M | -73.79M | 13.74M | -89.38M | -118.63M |
| Pretax profit | -46.74M | -61.52M | -65.60M | 33.17M | -75.78M | -105.93M |
| Tax | 98.00K | 139.00K | 108.00K | 170.00K | 190.00K | 234.00K |
| Net profit | -46.83M | -61.66M | -65.71M | 33.00M | -75.97M | -106.16M |
| Basic EPS | -1 | -1 | -1 | 0 | -1 | -1 |
| Diluted EPS | -0.81 | -1.08 | -1.11 | 0.47 | -1.05 | -1.47 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 38.42M | 109.25M | 93.09M | 473.61M | 891.21M | 1.57B |
| Cash & ST investments | 37.45M | 107.31M | 90.84M | 467.32M | 883.52M | 1.45B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 38.70M | 111.16M | 97.85M | 482.02M | 903.33M | 1.58B |
| Total current liabilities | 3.04M | 8.66M | 13.01M | 24.74M | 36.02M | 63.29M |
| Short-term debt | 147.00K | 349.00K | 260.00K | 1.44M | 1.70M | 2.88M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 61,173,000.00 | 175,890,000.00 | 212,985,000.00 | 29,051,000.00 | 38,487,000.00 | 67,541,000.00 |
| Total equity | -22.47M | -64.74M | -115.14M | 452.97M | 864.84M | 1.52B |
| Retained earnings | -22.95M | -64.74M | -116.95M | -206.57M | -329.10M | -470.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 849.62M | 799.30M | 814.02M | 1.57B | 1.49B | 1.37B |
| Cash & ST investments | 836.88M | 786.50M | 799.04M | 1.45B | 1.46B | 1.34B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 866.55M | 816.44M | 832.16M | 1.58B | 1.51B | 1.43B |
| Total current liabilities | 36.49M | 39.03M | 57.53M | 63.29M | 56.98M | 66.11M |
| Short-term debt | 2.47M | 2.66M | 2.80M | 2.88M | 2.61M | 2.60M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 41,911,000.00 | 44,362,000.00 | 62,140,000.00 | 67,541,000.00 | 61,030,000.00 | 71,011,000.00 |
| Total equity | 824.64M | 772.08M | 770.02M | 1.52B | 1.45B | 1.35B |
| Retained earnings | -375.93M | -437.59M | -503.30M | -470.30M | -546.27M | -652.43M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -14.28M | -32.16M | -46.12M | -79.49M | -116.64M | -222.20M |
| Depreciation & amortization | 0 | 72.00K | 277.00K | 295.00K | 992.00K | 1.33M |
| Free cash flow | -14.30M | -33.37M | -46.28M | -81.66M | -117.93M | -225.81M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 472.30M | 514.57M | 665.71M |
| Ending cash balance | 16.35M | 105.31M | 26.09M | 129.79M | 169.51M | 799.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -52.23M | -54.56M | -51.00M | -64.42M | 15.23M | -120.12M |
| Depreciation & amortization | 274.00K | 291.00K | 356.00K | 412.00K | 576.00K | 551.00K |
| Free cash flow | -52.54M | -54.79M | -52.57M | -65.91M | 14.05M | -120.07M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 608.65M | -- | -- |
| Ending cash balance | 152.12M | 147.02M | 102.91M | 799.62M | 316.17M | 272.64M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -53.06 | -18.60 | -11.86 |
| ROA %i | -41.44 | -58.41 | -50.56 | -30.91 | -17.69 | -11.35 |
| ROIC %i | -- | -- | -- | -52.17 | -18.46 | -11.81 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 12.64 | 12.62 | 7.16 | 19.14 | 24.74 | 24.81 |
| Quick ratioi | 12.32 | 12.39 | 6.98 | 18.89 | 24.53 | 24.43 |
| Debt / assetsi | 0.72 | 0.56 | 0.27 | 1.13 | 0.43 | 0.41 |
| LT debt / equityi | -- | -- | -- | 0.89 | 0.25 | 0.24 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -22.85 | -21.14 | -25.28 | -11.86 | -15.00 | -20.21 |
| ROA %i | -21.65 | -20.30 | -23.87 | -11.35 | -14.35 | -19.17 |
| ROIC %i | -22.62 | -20.99 | -25.11 | -11.81 | -14.91 | -20.07 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 23.29 | 20.48 | 14.15 | 24.81 | 26.16 | 20.75 |
| Quick ratioi | 22.94 | 20.15 | 13.89 | 24.43 | 25.59 | 20.31 |
| Debt / assetsi | 0.88 | 0.94 | 0.85 | 0.41 | 0.38 | 0.44 |
| LT debt / equityi | 0.62 | 0.65 | 0.56 | 0.24 | 0.22 | 0.27 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:34:29 · For reference only, not investment advice and not tailored to your situation.